Dysregulation of PTH—whether through excess secretion in hyperparathyroidism or deficiency in hypoparathyroidism—leads to distinct metabolic alterations that compromise skeletal integrity, even before visible structural damage appears (1–3). The gene discussed is PTH; the disease is hypoparathyroidism.